In the context of cancer vaccine, the heterologous ChAdOx1-MVA vaccination regimen targeting the oncofetal self-antigen 5T4 has been tested in early-stage prostate cancers and found to be safe and immunogenic, with the detection of ex vivo T cell responses to the vaccine-encoded tumor-associated antigen 5T4 [50]. The gene discussed is TPBG; the disease is prostate cancer.